Nicholas Wallingford

ORCID: 0000-0003-2279-0480
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Proteoglycans and glycosaminoglycans research
  • Neuropeptides and Animal Physiology
  • Regulation of Appetite and Obesity
  • Cell Adhesion Molecules Research
  • Tissue Engineering and Regenerative Medicine
  • Sleep and Wakefulness Research
  • Fibroblast Growth Factor Research
  • Hearing, Cochlea, Tinnitus, Genetics
  • Hearing Loss and Rehabilitation
  • Neurofibromatosis and Schwannoma Cases
  • Noise Effects and Management
  • Neuroscience and Neuropharmacology Research
  • Glycosylation and Glycoproteins Research
  • Biochemical Analysis and Sensing Techniques

Pfizer (United States)
2018

Yale University
2009

Oregon National Primate Research Center
2004-2008

Oregon Health & Science University
2004-2008

University of Cincinnati Medical Center
2002

The anorexigenic neuromodulator alpha-melanocyte-stimulating hormone (alpha-MSH; referred to here as alpha-MSH1-13) undergoes extensive posttranslational processing, and its in vivo activity is short lived due rapid inactivation. enzymatic control of alpha-MSH1-13 maturation inactivation incompletely understood. Here we have provided insight into through the generation analysis a subcongenic mouse strain with reduced body fat compared controls. Using positional cloning, identified maximum 6...

10.1172/jci37209 article EN Journal of Clinical Investigation 2009-07-20

Abstract The CD44 transmembrane glycoprotein family has been implicated in cell‐cell adhesion and cell signaling response to components of the extracellular matrix but its role nervous system is not understood. proteins are elevated Schwann cells oligodendrocytes following insults, inflammatory demyelinating lesions, tumors. Here, we tested hypothesis that expression influences oligodendrocyte functions by generating transgenic mice express under control 2′,3′‐cyclic...

10.1002/glia.20042 article EN Glia 2004-04-30

Despite the prevalence of hearing loss, there are no FDA-approved chemical entities available for either otoprotection or treatment impairment. This lack drug-based treatments has made assessment middle and inner ear a rare, challenging exercise in pharmaceutical industry. Recently, advances use various decalcifying agents, as well heating techniques utilizing microwave technology have proven to be effective at shortening processing times, minimizing tissue damage potentially lowering cost...

10.1080/01478885.2018.1470133 article EN Journal of Histotechnology 2018-05-25
Coming Soon ...